FERAHEME is the only IV iron with patient-reported outcome data in the label1

In IDA Trial 1 and the extension trial, just 1 gram of FERAHEME demonstrated:

Raised Hgb levels ≥2 g/dL at any
time from baseline to Week 51

81.1 %

FERAHEME

VS
5.5 %

Placebo

See results

Improvements in FACIT-Fatigue
score from baseline1

11.7 points

FERAHEME

VS
6.8 points

Placebo

See results

Durability of response2

61 %

of patients did not
require a second
course of treatment
over a 6-month period

See results

IDA TRIAL 1
The majority of FERAHEME-treated patients experienced an increase of ≥2 g/dL Hgb at any time from baseline to Week 51

  • 81.1%

    493 patients
    FERAHEME Baseline Hgb: 8.9 (n=608)

  • 5.5%

    11 patients
    Placebo Baseline Hgb: 8.8 (n=200)

75.6%DIFFERENCE

(95% Cl, 71.2
to 80.0)

Fatigue-related symptoms and impacts were assessed with FACIT-Fatigue1,3*

In a 5-week study, patients treated with FERAHEME reported greater improvement from baseline in fatigue score than patients in the placebo arm1,3

  • 11.7points

    (SD: 11.73)
    FERAHEME (n=608)

  • 6.8points

    (SD: 9.51)
    Placebo (n=200)

4.9-pointDIFFERENCE*

(95% Cl, 3.08
to 6.71)

*Scores range from 0 to 52, with higher scores indicating less fatigue. 

EXTENSION TRIAL
Duration of response in a 6-month extension trial4

For 61% of patients who were treated with FERAHEME in IDA Trial 1, mean Hgb remained stable throughout the extension study without further treatment4

Monthly Hgb levels following a single course of FERAHEME5

Bars represent 95% CI; Month 1 refers to both IDA Trial 1 endpoint (Week 5) and the extension study baseline.

61% of FERAHEME-treated patients

did not require a second course of treatment over the 6-month study period2

Select Important Safety Information: FERAHEME may cause clinically significant hypotension. Monitor patients for signs and symptoms of hypotension following each FERAHEME administration.

See long-term safety profile with repeat dosing

CI=confidence interval; FACIT=Functional Assessment of Chronic Illness Therapy; Hgb=hemoglobin; IDA=iron deficiency anemia; SD=standard deviation.

back to top

With flexible dosing, patients can get FERAHEME as early as 3 days apart.2

LEARN MORE

References: 1. Feraheme [prescribing information]. AMAG Pharmaceuticals, Inc; September 2020. 2. Vadhan-Raj S, Ford DC, Dahl NV, et al. Safety and efficacy of ferumoxytol for the episodic treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy: results of a phase III, open-label, 6-month extension study. Am J Hematol. 2016;91(2):E3-E5. 3. Vadhan-Raj S, Strauss W, Ford D, et al. The efficacy and safety of IV ferumoxytol for adults with iron deficiency anemia previously unresponsive to or unable to tolerate oral iron. Am J Hematol. 2014;89(1):7-12. 4. Vadhan-Raj S, Dahl NV, Lau G, et al. Safety and efficacy of ferumoxytol for the episodic treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy: results of a phase III open-label, six month extension study. Poster presented at: American Society of Hematology Annual Meeting; December 8, 2013; New Orleans, LA. 5. Vadhan-Raj S, Dahl NV, Jiang J, Strauss W. Sustained improvements in fatigue and quality of life in iron deficiency anemia patients following a single course of ferumoxytol: results of a 6-month extension study. Poster presented at: American Society of Hematology Annual Meeting; December 1, 2018; San Diego, CA.